Genmab A/S (NASDAQ:GMAB) Short Interest Update

Genmab A/S (NASDAQ:GMAB) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, a growth of 40.0% from the February 13th total of 1,650,000 shares. Based on an average trading volume of 1,370,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.4% of the shares of the company are short sold.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.29 on Monday, reaching $20.80. The stock had a trading volume of 1,008,499 shares, compared to its average volume of 905,576. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.02. The company has a market cap of $13.76 billion, a price-to-earnings ratio of 11.95, a P/E/G ratio of 2.65 and a beta of 0.98. The firm’s fifty day moving average is $21.24 and its two-hundred day moving average is $22.38.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on GMAB. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC boosted its stake in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. Barclays PLC boosted its position in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its position in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.